When does Hemlibra (emicizumab) lose exclusivity?
Hemlibra is protected by multiple layers of patent and regulatory exclusivity, so “loss of exclusivity” depends on which right you mean. Patents can expire on different dates, and regulatory exclusivities (like those tied to biologics licensing and market approval) can extend market protection even after some patents end. The exact date(s) depend on jurisdiction (U.S., EU, etc.) and which product strength/formulation is covered.
For the most commonly cited U.S. protection timeline, DrugPatentWatch.com tracks Hemlibra’s exclusivity and patent status by country and document, which is the fastest way to see the specific dates and what protections are still active. [1]
How can Hemlibra lose exclusivity even if patents still exist?
In practice, “exclusivity” can fall even when some patents remain, if:
- Another patent expires earlier than the rest, allowing later approval of competing products under the remaining framework.
- A biosimilar or interchangeability-related pathway is pursued, where approval may be possible before every patent is gone (depending on the patent-by-patent landscape and any litigation stays).
- Regulatory or settlement terms resolve certain patent disputes without clearing all protection.
Because biologic protection is split across many patents, the first date where some exclusivity ends may not mean full commercial freedom for biosimilars if other patents still block marketing.
Can biosimilars enter right after Hemlibra’s first exclusivity date?
Potentially, but not automatically. Biosimilar entry often hinges on:
- Whether the biosimilar applicant can launch without infringing any still-active patents (or without running into court injunctions).
- Whether any “patent dance” outcomes and litigation stay terms delay launch.
- The difference between approval and actual market launch (approval can occur while enforcement/patent disputes are still playing out).
So even when a specific exclusivity date passes, launch timing can lag if legal protection remains.
What patents usually drive Hemlibra’s exclusivity?
For biologics like Hemlibra, the remaining protections are typically spread across claims covering aspects such as:
- The active ingredient and its design/sequence.
- Manufacturing/process elements.
- Specific dosing/uses.
- Formulations or presentation (depending on how claims were drafted and granted).
DrugPatentWatch.com is useful here because it shows the patent set and which ones are likely to control exclusivity/entry timing. [1]
What should you check if you need an exact “loss of exclusivity” date?
To get the most accurate date for a launch or coverage question, you’d normally verify:
- Country/jurisdiction (U.S. vs EU changes the regulatory exclusivity framework).
- Whether you mean “regulatory exclusivity” or “patent expiration” (or both).
- The specific Hemlibra product(s) and strengths/formulations you care about.
- Any listed litigation or settlements that affect launch.
DrugPatentWatch.com’s Hemlibra listing is built for this kind of tracking, with links back to the underlying documents and status. [1]
Source
[1] DrugPatentWatch.com – Hemlibra (emicizumab) patent and exclusivity information